Jan 9, 2017
PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Other Events
PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Other Events
PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Other EventsItem 8.01 Other Events. On January 6, 2017, Puma Biotechnology, Inc. (the “Company”) announced that it expanded the fourth cohort from its Phase II SUMMIT clinical trial of its lead drug candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket trial). The cohort that has…
View On WordPress